1. NEWS: Global Fund Board Approvesround 10 Proposals

1. NEWS: Global Fund Board Approvesround 10 Proposals

GLOBAL FUND OBSERVER (GFO), an independent newsletter about the Global Fund provided by Aidspan to over 8,000 subscribers in 170 countries.

Issue 135: 16 December 2010. (For formatted web, Word and PDF versions of this and other issues, see

+ + + + + + + + + + + + + + + + + + +

CONTENTS

+ + + + + + + + + + + + + + + + + + +

1. NEWS: Global Fund Board ApprovesRound 10 Proposals

The Global Fund Board has approved all 79 Round 10 proposals recommended by the Technical Review Panel (TRP), at a cost of $1.73 billion over the first two years and $4.72 billion over five years. This makes Round 10 the third largest round ever, after Rounds 8 and 9 respectively.

2. NEWS: Global Fund Board Decides Timing of Round 11

The Global Fund Board has decided that Round 11 will be launched on 15 August 2011, with proposals to be submitted by 15 December 2011 and approvals to be decided by the Board at its meeting in about May 2012.

3. NEWS: Round 10 Results, by Country

Details are provided of the Board's decision regarding each eligible Round 10 proposal.

4. EDITOR’S NOTE: Further Board Decision News Forthcoming

GFO’s next issue, targeted for publication tomorrow, 17 December, will provide information on the other key decisions made at the 13-15 December Board meeting.

+ + + + + + + + + + + + + + + + + + +

1. NEWS: Global Fund Board Approves Round 10 Proposals

+ + + + + + + + + + + + + + + + + + +

The Global Fund Board has approved all 79 Round 10 proposals recommended by the Technical Review Panel (TRP), at a cost of $1.73 billion over the first two years and $4.72 billion over five years. This makes Round 10 the third largest round ever, after Rounds 8 and 9 respectively.

These decisions were made at the Fund’s 22nd board meeting, held on 13-15 December in Sofia, Bulgaria.

Unlike in previous rounds, the Fund did not have to delay approval of certain proposals pending further funding becoming available; sufficient funding will be available to cover all Round 10 proposals that the TRP recommended for approval. Also, the Board has not required that budgets be reduced across all the approved proposals.

The Board's decision as to which proposals to approve was, as always, entirely based on the advice it received from the TRP, an independent and non-political body of 43 experts from around the world who serve in their personal capacities. No Board members or Secretariat employees are members of the TRP. As always, the TRP did not take into consideration the availability or otherwise of funding when determining which proposals to recommend for approval.

Some of the highlights of the Round 10 approvals were as follows:

  • The TRP reviewed 150 proposals, of which 78 were for HIV/AIDS, 48 for TB, and 24 for malaria.
  • The average Round 10 approved proposal has a two-year cost of $22 million, down from $26 million in Round 9 and $33 million in Round 8, but still double the $11 million average cost of the prior seven rounds.
  • Fifty-three percent of eligible proposals submitted in Round 10 were approved, about the same as in Rounds 8 and 9. Malaria proposals were by far the most successful in Round 10, with 79% approved (as against 54% for TB proposals and 44% for HIV/AIDS). Over the last three rounds, malaria and TB proposal success rates have always been above 50%, but HIV/AIDS proposal success rates have always been below 50%.
  • However, HIV/AIDS had more proposals approved (34) than either TB (26) or malaria (19). In dollar terms, approved HIV/AIDS proposals accounted for 47% of the total cost, with malaria at 34% and TB at 20%.
  • From Round 8 to Round 9 to Round 10, the percentage of eligible proposals from Africa that was approved steadily fell from 58% to 54% to 45%. In the Middle East and Northern Africa region, the percentage approved dipped and then rebounded dramatically, from 57% to 28% to 64%. In Latin America and the Caribbean, the percentage approved did the opposite, going from 34% to 57% to 38%. Easily the best-performing region each time was East Asia and the Pacific, with approval rates of 75%, 65% and 78% in Rounds 8, 9 and 10, respectively.
  • Fifty-six percent of Round 10 proposals from non-Francophone countries were approved, as against only 48% of proposals from Francophone countries. These rates were almost identical to those that applied in Round 9.
  • Fifty-five percent of the total two-year cost of approved Round 10 proposals was for proposals from low-income countries, down from 70% in Round 9. The success rate of Round 10 proposals from low-income countries was 52%, about five percent less than the success rate of proposals from lower-middle and upper-middle income countries.
  • Twenty-five of the 78 HIV proposals requested funding from the dedicated funding stream for most-at-risk-populations (MARPs), which was newly created for Round 10. The total two-year funding request under this stream was $99 million. The TRP recommended 12 of these proposals, with a two-year cost of $47 million. Two of the successful MARPs proposals were from Malaysia and Uruguay; this will be the first time that these countries will receive money from the Global Fund.
  • Of the 150 eligible proposals, 52 (35%) planned to implement dual-track financing, with principal recipients from both the governmental and non-governmental sectors.

The following tables summarise the Round 10 results.

Table 1: Global Fund proposals, submitted and approved, by Round

Round / Eligible proposals submitted / Of which, approved by the Board
Number / Total Cost * / Aver. cost per proposal / Number
(and % of no. submitted) / Total Cost
(and % of submitted cost) / Aver. cost per proposal
1 / 204 / $1.5 b. / $7 m. / 58 (28%) / $0.6 b. (38%) / $10 m.
2 / 229 / $2.1 b. / $9 m. / 98 (43%) / $0.9 b. (40%) / $9 m.
3 / 180 / $1.8 b. / $10 m. / 71 (39%) / $0.6 b. (33%) / $9 m.
4 / 173 / $2.5 b. / $15 m. / 69 (40%) / $1.0 b. (39%) / $14 m.
5 / 202 / $3.3 b. / $16 m. / 63 (31%) / $0.7 b. (22%) / $12 m.
6 / 196 / $2.5 b. / $13 m. / 85 (43%) / $0.8 b. (34%) / $10 m.
7 / 150 / $2.4 b. / $16 m. / 73 (49%) / $1.1 b. (47%) / $15 m.
8 / 174 / $5.8 b. / $33 m. / 94 (54%) / $3.1 b. (51%) / $33 m.
9 / 159 / $4.8 b. / $31 m. / 85 (53%) / $2.2 b. (46%) / $26 m.
10 / 150 / $4.3 b / $29 m. / 79 (53%) / $1.73 b (40%) / $22 m.

* In this and the following tables, "Cost" means the cost for Years 1-2.

Table 2: Number of proposals submitted and approved, by disease, Rounds 8-10

Number of eligible proposals submitted, number approved, and % approved
Disease / Round 8 / Round 9 / Round 10
Submitted / Approved / Submitted / Approved / Submitted / Approved
HIV/AIDS / 76 / 37 / (49%) / 74 / 35 / (47%) / 78 / 34 / (44%)
Malaria / 41 / 28 / (68%) / 31 / 17 / (55%) / 24 / 19 / (79%)
TB / 57 / 29 / (51%) / 54 / 33 / (61%) / 48 / 26 / (54%)
Total / 174 / 94 / (54%) / 159 / 85 / (53%) / 150 / 79 / (53%)

Table 3: Costs of approved proposals, by disease, Rounds 8-10

Cost of approved proposals, % split between diseases
Disease / Round 8 / Round 9 / Round 10
HIV/AIDS / $1.16 b. / (38%) / $0.98 b. / (44%) / $0.81 b. / (47%)
Malaria / $1.57 b. / (51%) / $0.61 b. / (28%) / $0.58 b. / (34%)
TB / $0.33 b. / (11%) / $0.62 b. / (28%) / $0.34 b. / (20%)
Total / $3.06 b. / (100%) / $2.21 b. / (100%) / $1.73 b. / (100%)

Table 4: Regional breakout, Rounds 9 and 10

Region / Number of eligible proposals submitted,
number approved, and % approved / Cost of approved proposals,
% split between regions
Round 9 / Round 10 / Round 9 / Round 10
Submitted / Approved / Submitted / Approved
Africa: Eastern / 16 / 8 / (50%) / 20 / 9 / (45%) / $0.38 b. / (17%) / $0.33 b. / (19%)
Africa: Southern / 13 / 7 / (54%) / 20 / 7 / (35%) / $0.26 b. / (12%) / $0.34 b. / (20%)
Africa: West and Central / 32 / 18 / (56%) / 22 / 12 / (55%) / $0.59 b. / (27%) / $0.27 b. / (16%)
East Asia and the Pacific / 17 / 11 / (65%) / 18 / 14 / (78%) / $0.38 b. / (17%) / $0.21 b. / (12%)
Eastern Europe and Central Asia / 21 / 12 / (57%) / 19 / 10 / (53%) / $0.11 b. / (5%) / $0.21 b. / (12%)
Latin America and the Caribbean / 30 / 17 / (57%) / 21 / 8 / (38%) / $0.19 b. / (9%) / $0.04 b. / (2%)
Middle East and Northern Africa / 18 / 5 / (28%) / 22 / 14 / (64%) / $0.09 b. / (4%) / $0.26 b. / (15%)
South West Asia / 12 / 7 / (58%) / 8 / 5 / (63%) / $0.22 b. / (10%) / $0.08 b. / (5%)
Total: / 159 / 85 / (53%) / 150 / 79 / (53%) / $2.21 b. / (100%) / $1.73 b. / (100%)

Table 5: Francophone/Non-Francophone breakout, Rounds 9 and 10

Language of country / Number of eligible proposals submitted,
number approved, and % approved / Cost of approved proposals,
% split between country type
Round 9 / Round 10 / Round 9 / Round 10
Submitted / Approved / Submitted / Approved
Francophone countries * / 35 / 17 / (49%) / 23 / 11 / (48%) / $0.60 b. / (27%) / $0.32 b. / (18%)
Non-Francophone countries / 112 / 64 / (57%) / 112 / 63 / (56%) / $1.53 b. / (69%) / $1.39 b. / (80%)
Regional / 12 / 4 / (33%) / 15 / 5 / (33%) / $0.08 b. / (4%) / $0.02 b. / (1%)
Total: / 159 / 85 / (53%) / 150 / 79 / (53%) / $2.21 b. / (100%) / $1.73 b. / (100%)

* From the countries applying under Round 10, the following countries were classified by GFO as Francophone: Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo Rep., Congo DR, Cote d'Ivoire, Djibouti, Guinea, Madagascar, Mali, Niger, Senegal and Togo.

Table 6: Breakout by national income level, Rounds 9 and 10

Income level / Number of eligible proposals submitted,
number approved, and % approved / Cost of approved proposals,
% split between country type
Round 9 / Round 10 / Round 9 / Round 10
Submitted / Approved / Submitted / Approved
Low / 83 / 44 / (53%) / 67 / 35 / (52%) / $1.54 b. / (70%) / $0.96 b. / (55%)
Lower-middle / 57 / 34 / (60%) / 56 / 32 / (57%) / $0.51 b. / (23%) / $0.55 b. / (32%)
Upper-middle / 9 / 3 / (33%) / 12 / 7 / (58%) / $0.08 b. / (4%) / $0.21 b. / (12%)
Regional / 12 / 4 / (33%) / 15 / 5 / (33%) / $0.08 b. / (4%) / $0.02 b. / (1%)
Total: / 159 / 85 / (53%) / 150 / 79 / (53%) / $2.21 b. / (100%) / $1.73 b. / (100%)

Further highlights of Round 10 include the following:

  • Each member of each CCM that applied in Round 10 will shortly be sent formal notification of the Board's decision, together with a TRP Review Form in which the TRP will provide detailed explanations for the decision, together with a list of any major and minor weaknesses that the TRP found in the proposal. In the case of Category 1, 2 and 2B proposals, weaknesses will include issues that must be addressed during the clarification process. In the case of Category 3 proposals, weaknesses will include issues that would have to be addressed in any re-submission in a future round.
  • In Round 10, four approved proposals had five-year requested amounts in excess of $250 million, up from two in Round 9 and down from seven in Round 8. The four proposals, all for HIV, were from Kenya ($345 m.), Ukraine ($306 m.), South Africa ($303 m.) and Zambia $259 m.).
  • Among non-approved Round 10 proposals, Ghana had a five-year request amounting to $1.4 billion for an HIV proposal with a cross-cutting health systems strengthening (HSS) request attached (it was rated Category 4 by the TRP). Four other countries had five-year requested amounts in excess of $250 million: Democratic Republic of Congo, Malawi, Nigeria and Zimbabwe, all for HIV proposals.)
  • None of the three eligible proposals submitted by regional coordinating mechanisms (RCMs) were approved. Of the 12 proposals submitted by regional organisations, five were approved.
  • There were two eligible proposals from Non-CCMs. Both were from one applicant in Somalia and both were approved. One was for TB, and the other was for malaria, with a cross-cutting HSS component attached. Six Non-CCM applicants submitted proposals, but five were deemed ineligible.
  • Of the 28 cross-cutting HSS requests that were attached to eligible proposals, 11 were approved, with a two-year cost of $128 million. This is down considerably from Round 9 (17 proposals approved, with a two-year cost of $363 million).
  • Of the 150 proposals reviewed by the TRP, 12 were consolidated proposals, of which eight were approved for funding.
  • Of the 150 proposals reviewed by the TRP, 64 were re-submissions of proposals that were unsuccessful in Round 9. Of these, the success rate for disease proposals was 64% and for cross-cutting HSS requests was 55%. Thus, a significant percentage of re-submissions still did not succeed this second time.
  • In five of the six regions that submitted MARPs proposals in Round 10, the average two-year cost of all approved HIV proposals in these regions was down from Round 9 – down significantly in some regions (e.g., Latin America and the Caribbean, from $14 million to $4 million; East Asia and Pacific, from $29 million to $14 million; and Middle East and Northern Africa, from $27 million to $10 million). Round 10 applicants were allowed to submit a regular HIV proposal or a MARPs proposal, but not both. Given that the MARPs proposals were each capped at $5 million for the first two years, it is reasonable to conclude that the use of MARPs proposals has lowered the average cost of HIV proposals in many regions.
  • Interventions to strengthen community systems (CSS) were included in 65 of the 150 eligible disease proposals (43%) and in six of the 28 cross-cutting HSS requests (21%). (The Board approved funding 27 of the 65 disease proposals, and one of the six HSS requests.)

The Phase 1 budget breakout of the Round 10 approved proposals is shown in Table 7.

Table 7: Budget breakdown, Rounds 8, 9 and 10

Category / Round 8 / Round 9 / Round 10
Health products and health equipment / 36% / 21% / 19%
Medicines and pharmaceutical products / 11% / 13% / 22%
Training / 9% / 10% / 10%
Human resources / 8% / 14% / 13%
Infrastructure and other equipment / 8% / 10% / 6%
Procurement and supply management costs / 6% / 4% / 5%
M&E / 5% / 7% / 6%
Communication materials / 4% / 4% / 3%
Planning and administration / 3% / 5% / 6%
Living support to clients and target populations / 3% / 4% / 3%
Technical and management assistance / 3% / 3% / 3%
Overheads / 3% / 4% / 3%
Other / 1% / 1% / 1%
Total / 100% / 100% / 100%

Note: The Round 10 breakout numbers are based on total costs of $1.85 billion, whereas only $1.73 billion was approved. The $1.85 billion figure includes already approved and committed funds under the eight consolidated disease proposals recommended for funding, as well as, in fourteen instances, elements identified and removed by the TRP from otherwise technically sound proposals recommended for funding by the TRP.

+ + + + + + + + + + + + + + + + + + +

2. NEWS: Global Fund Board Decides Timing of Round 11

+ + + + + + + + + + + + + + + + + + +

The Global Fund Board has decided that Round 11 will be launched on 15 August 2011, with proposals to be submitted by 15 December 2011 and approvals to be decided by the Board at its meeting in about May 2012.

The second wave of National Strategy Applications (NSA) will be initiated in January 2011, with approvals to be decided by the Board at its meeting in about May 2012.

Round 12 will then be launched at or before the end of 2013, with the actual timing to depend on funding availability.

+ + + + + + + + + + + + + + + + + + +

3.NEWS: Round 10 Results, by Country

+ + + + + + + + + + + + + + + + + + +

Based on advice from the TRP, the Board divided eligible Round 10 proposals into five categories, as follows:

  • Category 1: Approved proposals requiring no or minor clarifications; any clarifications need to be provided within eight weeks and then given a final approval by the TRP Chair or Vice-Chair.
  • Category 2: Proposals that are approved subject to the required clarifications being provided within a limited timeframe (six weeks for the applicant to provide an initial detailed response to the TRP queries, and a further three months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
  • Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
  • Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in a future round following major revision.
  • Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.

The Board approved all proposals in Categories 1, 2 and 2B.

Table 8 provides a summary of the Round 10 results by category. Tables 9 and 10 show the results for each applicant.

Table 8: Round 10 results by category

Category / Number of proposals / TRP-recommended funding
(Years 1-2) / (Years 1-5)
Approved: Category 1 / 3 / $0.05 b. / $0.14 b.
Approved: Category 2 / 49 / $1.03 b. / $2.73 b.
Approved: Category 2B / 27 / $0.65 b. / $1.85 b.
Subtotal: All Approved Proposals: / 79 / $1.73 b. / $4.72 b.
Not Approved: Category 3 / 56 / $1.64 b. / $4.21 b.
Not Approved: Category 4 / 15 / $0.78 b. / $2.22 b.
Not Approved: Parts of Category 1, 2 and 2B proposals not recommended for funding * / n/a / $0.14 b. / $0.48 b.
Subtotal: All Non-Approved Proposals: / 71 / $2.56 b. / $6.91 b.
Total: All Proposals / 150 / $4.30 b. / $11.63 b.

*This refers to a situation where a disease proposal with an HSS request attached has been submitted, and the TRP has recommended, and the Board has approved, either the disease proposal or the HSS request, but not both.

Table 9: Round 10 results, by country

Notes:

1. In the following table, DP = disease part.

2. For approved proposals, the costs shown in the last two columns are the amounts recommended by the TRP. For proposals that were not approved, the costs are the amounts requested by the applicant.

Applicant / Disease component / Applicant type / Decision / Cate-gory / Cost
(Years 1-2) / (Years 1-5)
Afghanistan / TB (DP + HSS part) / CCM / Approved / 2 / € 16,132,533 / € 23,330,719
Angola / HIV / CCM / Approved / 2B / $25,877,952 / $68,884,971
Angola / Malaria / CCM / Approved / 1 / $40,435,549 / $111,239,055
Argentina / HIV MARPs / CCM / Approved / 2 / $4,933,812 / $12,500,000
Armenia / HIV MARPs / CCM / Not approved / 3 / € 2,328,230 / € 4,817,816
Armenia * / TB (DP) / CCM / Approved / 2 / € 3,310,881 / € 8,881,651
Armenia / TB (HSS part) / CCM / Not approved / n/a / € 1,180,614 / € 2,159,904
Azerbaijan / HIV MARPs / CCM / Not approved / 3 / $3,546,724 / $12,466,986
Azerbaijan / Malaria / CCM / Not approved / 3 / € 1,880,538 / € 3,571,100
Bangladesh ** / TB / CCM / Approved / 2B / $11,677,496 / $98,543,757
Belize / HIV MARPs / CCM / Not approved / 3 / $2,602,746 / $6,722,026
Belize / TB / CCM / Not approved / 4 / $2,823,065 / $5,960,681
Benin / HIV / CCM / Not approved / 3 / € 11,286,254 / € 21,692,352
Benin / TB / CCM / Not approved / 3 / € 993,858 / € 2,274,009
Bosnia & Herz. / HIV / CCM / Not approved / 4 / € 2,800,310 / € 5,497,810
Botswana / HIV / CCM / Not approved / 3 / $47,926,893 / $137,642,491
Botswana / TB / CCM / Not approved / 3 / $10,828,604 / $25,258,210
Brazil / HIV MARPs / CCM / Not approved / 3 / $5,000,000 / $12,500,000
Burkina Faso / HIV (DP) / CCM / Approved / 2B / € 38,993,903 / € 97,448,392
Burkina Faso / HIV (HSS part) / CCM / Not approved / n/a / € 10,272,650 / € 24,384,963
Burundi / TB / CCM / Not approved / 3 / $4,830,351 / $13,212,893
Cambodia / HIV / CCM / Not approved / 3 / $23,124,597 / $47,452,279
Cambodia / TB (DP + HSS part) / CCM / Not approved / 3 / $47,313,760 / $132,570,309
Cameroon / HIV / CCM / Approved / 2B / € 30,200,540 / € 97,411,942
Cape Verde / Malaria / CCM / Approved / 2B / € 968,724 / € 1,414,366
Central Af. Rep. / HIV (DP + HSS part) / CCM / Not approved / 3 / € 29,077,778 / € 64,570,395
Chad / HIV / CCM / Not approved / 3 / € 31,801,787 / € 94,985,597
Chad / TB (DP + HSS part) / CCM / Not approved / 3 / € 11,599,749 / € 22,450,241
China / Malaria / CCM / Approved / 2B / $5,830,102 / $15,704,363
Colombia / TB / CCM / Approved / 2B / $5,390,584 / $11,271,656
Congo Rep. / HIV / CCM / Not approved / 3 / € 4,674,974 / € 9,978,943
Congo DR / HIV / CCM / Not approved / 3 / $111,533,674 / $295,297,357
Congo DR / Malaria / CCM / Approved / 2 / $73,922,870 / $185,122,386
Cote d'Ivoire / HIV (DP + HSS part) / CCM / Not approved / 3 / € 57,632,004 / € 133,432,755
Djibouti / TB / CCM / Approved / 2 / € 2,461,552 / € 6,080,117
Dominican Rep. / HIV MARPs / CCM / Not approved / 4 / $4,950,940 / $12,496,996
Eritrea * / HIV (DP + HSS part) / CCM / Approved / 2 / $20,818,140 / $59,897,311
Eritrea * ** / TB / CCM / Approved / 2B / $7,316,801 / $22,815,431
Ethiopia / HIV / CCM / Not approved / 3 / $88,149,150 / $176,458,326
Ethiopia / Malaria (DP + HSS part) / CCM / Not approved / 3 / $97,848,890 / $245,989,480
Ethiopia / TB / CCM / Not approved / 3 / $21,107,334 / $82,169,387
Georgia / HIV MARPs / CCM / Approved / 2 / € 3,105,210 / € 8,860,077
Georgia / TB / CCM / Approved / 2 / € 7,695,603 / € 21,727,729
Ghana / HIV (DP + HSS part) / CCM / Not approved / 4 / $499,428,723 / $1,420,138,447
Ghana * / TB / CCM / Approved / 2B / $31,897,744 / $77,418,445
Guinea / HIV (DP + HSS part) / CCM / Approved / 2B / $20,877,516 / $56,875,437
Guinea / Malaria / CCM / Approved / 2B / $32,046,938 / $46,625,648
Guinea Bissau / HIV (DP + HSS part) / CCM / Not approved / 3 / € 26,167,631 / € 63,815,647
Guyana / TB / CCM / Not approved / 4 / $486,607 / $1,050,801
Honduras / TB / CCM / Approved / 2B / $6,030,951 / $12,402,425
India / HIV / CCM / Not approved / 3 / $21,412,956 / $61,404,090
Indonesia / TB (DP + HSS part) / CCM / Approved / 2 / $47,727,271 / $157,544,680
Iran / Malaria / CCM / Approved / 2 / $9,363,548 / $19,578,464
Jordan / TB / CCM / Approved / 2 / $2,078,829 / $4,666,284
Kazakhstan / HIV MARPs / CCM / Approved / 2 / $2,404,755 / $12,449,062
Kenya / HIV / CCM / Approved / 2B / $93,376,285 / $345,103,871
Kenya / Malaria / CCM / Approved / 2 / $49,979,579 / $138,370,324
Kyrgyz Rep. / HIV / CCM / Approved / 2 / $11,207,840 / $41,480,486
Kyrgyz Rep. / TB / CCM / Not approved / 3 / $3,842,777 / $5,659,777
Lao PDR / TB (HSS part) / CCM / Not approved / n/a / $8,155,754 / $17,158,018
Lao PDR ** / TB (DP) / CCM / Approved / 2 / $3,255,999 / $12,887,910
Lesotho / HIV / CCM / Not approved / 3 / $29,594,699 / $65,273,286
Liberia / Malaria (DP + HSS part) / CCM / Approved / 2 / $28,698,063 / $68,892,692
Liberia / TB / CCM / Approved / 2B / $2,862,226 / $16,061,899
Macedonia / HIV MARPs / CCM / Approved / 1 / € 2,825,259 / € 9,407,934
Macedonia / TB / CCM / Approved / 2 / € 2,901,528 / € 6,112,713
Madagascar / HIV (DP + HSS part) / CCM / Not approved / 3 / $46,050,649 / $110,739,971
Malawi / HIV / CCM / Not approved / 3 / $164,254,176 / $561,450,164
Malaysia / HIV MARPs / CCM / Approved / 2B / $4,672,630 / $12,405,288
Maldives / HIV MARPs / CCM / Not approved / 3 / $2,880,814 / $8,044,746
Mali / Malaria / CCM / Approved / 2B / € 24,827,735 / € 94,873,243
Mali / TB / CCM / Approved / 2 / € 8,053,957 / € 13,773,341
Mauritius / HIV MARPs / CCM / Not approved / 3 / $2,870,148 / $12,435,364
Moldova / HIV MARPs / CCM / Not approved / 3 / $3,849,298 / $12,491,713
Mongolia / HIV / CCM / Not approved / 4 / $2,218,185 / $7,248,739
Mongolia ** / TB (DP + HSS part) / CCM / Approved / 2 / $3,696,354 / $9,052,049
Morocco / HIV / CCM / Approved / 2 / $14,672,516 / $43,597,649
Morocco / TB / CCM / Approved / 2 / $5,014,439 / $10,795,334
Mozambique / HIV / CCM / Not approved / 3 / $54,163,105 / $131,214,912
Mozambique / TB / CCM / Not approved / 3 / $25,407,092 / $69,822,783
Namibia / HIV / CCM / Not approved / 4 / $15,248,614 / $44,292,453
Namibia / TB / CCM / Approved / 2 / $12,524,672 / $32,994,241
Nepal / HIV / CCM / Approved / 2 / $16,150,553 / $57,273,249
Nicaragua / TB / CCM / Not approved / 3 / $4,106,578 / $8,247,665
Niger / HIV / CCM / Not approved / 3 / € 30,335,989 / € 73,945,907
Niger / Malaria / CCM / Not approved / 3 / € 72,627,052 / € 130,641,962
Niger / TB (DP + HSS part) / CCM / Approved / 2B / € 19,035,383 / € 42,226,096
Nigeria / HIV (DP + HSS part) / CCM / Not approved / 4 / $97,491,288 / $383,708,645
Pakistan * / Malaria (DP) / CCM / Approved / 2B / $23,395,667 / $51,516,709
Pakistan / Malaria (HSS part) / CCM / Not approved / n/a / $15,199,740 / $21,594,900
Panama / HIV MARPs / CCM / Approved / 2 / $4,202,744 / $10,273,513
Papua NG * / HIV (DP + HSS part) / CCM / Approved / 2 / $23,419,727 / $46,697,052
Peru / HIV MARPs / CCM / Approved / 2 / $4,999,999 / $12,499,997
Peru / Malaria / CCM / Not approved / 3 / $2,835,863 / $7,741,937
Peru / TB / CCM / Not approved / 3 / $15,481,203 / $29,837,075
Russian Fed. / TB / CCM / Approved / 2B / $63,472,958 / $126,926,245
Russian Fed. / TB / Sub-CCM / Not approved / 4 / € 20,170,145 / € 36,360,264
Sao Tome & P. / HIV / CCM / Approved / 2 / $1,279,852 / $2,476,713
Senegal / Malaria / CCM / Approved / 2 / € 21,650,781 / € 62,865,723
Senegal * ** / TB / CCM / Approved / 2 / € 6,335,035 / € 17,460,725
Sierra Leone / Malaria / CCM / Approved / 2 / $23,255,609 / $62,649,856
Sierra Leone / TB (DP + HSS part) / CCM / Not approved / 3 / $34,333,373 / $77,234,629
Somalia / Malaria (DP + HSS part) / Non-CCM / Approved / 2 / $39,333,002 / $84,550,325
Somalia * ** / TB / Non-CCM / Approved / 2B / $14,213,393 / $58,380,928
South Africa / HIV / CCM / Approved / 2 / $128,481,275 / $302,717,719
Sri Lanka / TB (DP + HSS part) / CCM / Not approved / 3 / $11,845,852 / $25,088,859
Sudan North / HIV / CCM / Approved / 2 / $21,944,538 / $61,919,606
Sudan North / Malaria / CCM / Approved / 2B / $61,256,082 / $182,841,841
Sudan South / HIV / Sub-CCM / Not approved / 4 / $65,528,320 / $135,697,425
Sudan South / Malaria / Sub-CCM / Approved / 2 / $26,486,653 / $98,618,453
Sudan South / TB / Sub-CCM / Not approved / 3 / $16,374,061 / $50,114,047
Swaziland / HIV / CCM / Not approved / 3 / $34,723,593 / $89,609,304
Swaziland ** / TB / CCM / Approved / 2 / $11,202,195 / $39,004,228
Syria * / HIV MARPs / CCM / Approved / 2B / $1,723,169 / $3,396,722
Tajikistan / HIV / CCM / Not approved / 3 / $20,521,257 / $64,745,498
Tajikistan / TB / CCM / Not approved / 3 / $49,913,253 / $115,418,678
Tanzania / HIV / CCM / Not approved / 3 / $50,880,157 / $113,178,230
Tanzania / TB / CCM / Not approved / 3 / $33,201,781 / $68,786,103
Thailand / HIV / CCM / Approved / 2 / $15,398,249 / $42,088,572
Thailand * / Malaria / CCM / Approved / 2B / $32,500,432 / $78,378,690
Thailand / TB / CCM / Approved / 2 / $12,344,773 / $31,716,829
Timor-Leste / HIV / CCM / Approved / 1 / $6,798,682 / $14,254,688
Timor-Leste * / Malaria / CCM / Approved / 2B / $7,170,680 / $22,349,915
Timor-Leste / TB / CCM / Not approved / 3 / $2,706,769 / $9,661,901
Togo / HIV / CCM / Not approved / 3 / € 6,280,885 / € 16,083,684
Tunisia / HIV MARPs / CCM / Not approved / 3 / $4,144,950 / $12,499,365
Uganda / HIV (DP) / CCM / Not approved / n/a / $55,834,292 / $217,300,859
Uganda / HIV (HSS part) / CCM / Approved / 2 / $17,917,965 / $25,251,193
Uganda / Malaria / CCM / Approved / 2 / $53,167,057 / $155,963,673
Uganda / TB / CCM / Approved / 2 / $10,391,585 / $24,757,129
Ukraine / HIV / CCM / Approved / 2 / $95,842,099 / $305,535,421
Uruguay / HIV MARPs / CCM / Approved / 2 / $3,953,375 / $9,572,417
Uzbekistan / HIV / CCM / Approved / 2 / $9,519,645 / $14,828,347
Vietnam / HIV (DP) / CCM / Not approved / n/a / $45,071,739 / $188,864,423
Vietnam / HIV (HSS part) / CCM / Approved / 2B / $42,102,165 / $86,636,150
Yemen / HIV (DP + HSS part) / CCM / Not approved / 3 / $14,565,766 / $32,312,943
Zambia * / HIV / CCM / Approved / 2 / $102,851,986 / $259,216,608
Zanzibar (Tanz.) / TB / CCM / Approved / 2 / $2,633,434 / $5,912,925
Zimbabwe / HIV (DP + HSS part) / CCM / Not approved / 3 / $118,402,303 / $342,054,472
Zimbabwe / Malaria / CCM / Approved / 2 / $14,550,666 / $24,960,569
Zimbabwe / TB / CCM / Not approved / 3 / $12,193,205 / $25,507,117
Total – 135 country-based proposals

*The TRP-recommended funding has been reduced from the requested amount because the TRP removed certain elements from the proposal.